Skip to navigation Skip to content

Clinical Trial: Electronic Pill Bottle


Treatment mode of action: To improve medication adherence
Number of Subjects: 100
Medication: Electronic Pill Bottle
Location: Maine|Massachusetts|New Hampshire|Rhode Island

Massachusetts General Hospital 
165 Cambridge St., 6th Floor, Boston, MA 02114

Contact Information
Dylan Rice
(617) 643-2947


National Multiple Sclerosis Society


People with MS have variable adherence to MS medications, making it challenging to determine the effectiveness of disease modifying therapies to assess true treatment failures. Whereas some people forget to take medications due to active lifestyles, others may have cognitive impairments that prevent them from organizing and planning their regular dosing schedules. An electronic pill cap ("Pillsy") has been developed to record pill taking, timing, and set reminders through a mobile app. Data on adherence can be captured and analyzed remotely for health care provider review. 
Investigators will enroll 100 adult patients, 18 years old and above, with multiple sclerosis, at the Massachusetts General Hospital MS Clinics in a pilot study of Pillsy electronic pill bottles. People with MS who are taking (1) fingolimod, (2) dimethyl fumarate, (3) teriflunomide, or (4) siponimod will be eligible. People must possess any type of smartphone capable of downloading the Pillsy application to be eligible. Participants will be asked to use the Pillsy bottle for 90 days each. At enrollment, participants will be randomized via random number generator 1:1 to either a) active monitoring with medication reminders or b) passive monitoring without medication reminders. Throughout the 90-day study period, the electronic pill bottles will monitor and record medication use. After 90 days, participants will be evaluated for user satisfaction.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.